Sfoglia per Autore  

Opzioni
Mostrati risultati da 21 a 40 di 156
Titolo Tipologia Data di pubblicazione Autori File
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 01 - Articolo su rivista 2020 Falanga A +
Laboratory haemostasis monitoring in COVID-19 01 - Articolo su rivista 2020 Falanga A +
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 01 - Articolo su rivista 2020 Falanga, A +
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 01 - Articolo su rivista 2020 Falanga A +
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 01 - Articolo su rivista 2020 Falanga A. +
Clozapine-induced anemia: A case-report 01 - Articolo su rivista 2020 Falanga A +
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 01 - Articolo su rivista 2020 Falanga A +
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine 01 - Articolo su rivista 2020 Falanga A. +
DOACs and “newer” hemophilia therapies in COVID-19: Reply 01 - Articolo su rivista 2020 Falanga A +
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 01 - Articolo su rivista 2019 Falanga, A +
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 01 - Articolo su rivista 2019 Falanga A +
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER) 01 - Articolo su rivista 2019 Falanga A. +
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 03 - Contributo in libro 2019 Falanga, A +
Treatment of venous thromboembolism with tinzaparin in oncological patients 01 - Articolo su rivista 2019 Falanga, AnnaMantovani, Lorenzo +
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 01 - Articolo su rivista 2019 Falanga, A +
Rituximab for treatment of autoimmune acquired platelet function disorders: description of two cases of acquired Glanzmann thrombasthenia and one case of acquired delta storage pool disease 01 - Articolo su rivista 2019 Falanga A. +
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 01 - Articolo su rivista 2019 Falanga, A +
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 01 - Articolo su rivista 2019 Falanga, A +
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 01 - Articolo su rivista 2019 Falanga A +
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 01 - Articolo su rivista 2019 Falanga, A +
Mostrati risultati da 21 a 40 di 156
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile